Downregulation of Src enhances the cytotoxic effect of temozolomide through AKT in glioma

6Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

Src is an attractive target since it is overexpressed in a number of malignancies, including glioma. However, the mechanism of Src signaling as well as its silencing effect on temozolomide in glioma is not well known. We hypothesized that downregulation of Src may enhance the cytotoxic effect of temozolomide on glioma. As expected, Src was overexpressed in glioblastoma multiforme (GBM) compared with normal brain tissues. Src silencing suppressed tumor proliferation and induced apoptosis in glioma. In addition, Src silencing combined with temozolomide treatment resulted in significant inhibition of tumor growth. These effects may be mediated by AKT which is a downstream effector of Src, since downregulation of AKT exhibited a similar effect as Src siRNA when combined with temozolomide. Finally, we demonstrated that overexpression of AKT suppressed the enhanced cytotoxic effect of temozolomide mediated by Src silencing. Thus, the present study demonstrated that Src plays a biologically significant role in tumor proliferation and apoptosis and enhances the cytotoxic effect of temozolomide through AKT supression in glioma. © 2013 Spandidos Publications Ltd. All rights reserved.

Author supplied keywords

Cite

CITATION STYLE

APA

Wang, Z., Sun, J., Li, X., Yang, S., Yue, S., Zhang, J., … Yang, W. (2013). Downregulation of Src enhances the cytotoxic effect of temozolomide through AKT in glioma. Oncology Reports, 29(4), 1395–1398. https://doi.org/10.3892/or.2013.2240

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free